A phase I dose-escalation and immune biomarker study of intravenous FF-10832, liposomal gemcitabine, in patients with advanced solid tumors.

Erkut Borazanci,Gerald Steven Falchook,Atif Abbas,Catherine Wheeler,Gary Maier,Mary J. Johansen,Paula Sedivy,Ruth Ann Subach,Shiraj Sen,Suzanne F. Jones,Tadaaki Ioroi,Takeshi Matsumoto,Takeaki Suzuki,Timothy Madden,Erika Paige Hamilton

A phase I dose-escalation and immune biomarker study of intravenous FF-10832, liposomal gemcitabine, in patients with advanced solid tumors.

2019

Erkut Borazanci
Gerald Steven Falchook
Atif Abbas
Catherine Wheeler
Gary Maier
Mary J. Johansen
Paula Sedivy
Ruth Ann Subach
Shiraj Sen
Suzanne F. Jones
Tadaaki Ioroi
Takeshi Matsumoto
Takeaki Suzuki
Timothy Madden
Erika Paige Hamilton

TPS3163Background: FF-10832 (832) is a liposomal formulation of gemcitabine (GEM) that demonstrates a prolonged half-life and preferential uptake in tumor vs normal tissues and marrow in pre-clinic...

Keywords:

Immune system
Oncology
Liposome
Gemcitabine
Pathology
Biomarker (medicine)
Internal medicine
Medicine
in patient
Cancer research
normal tissue
dose escalation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations